Biotech Business Developments: May 28 - June 4
📊 Analyzed 74 biotech business articles from 9 sources
Subscribe to Genomely for the latest discoveries and in-depth analyses in your inbox
Thank you for subscribing and for your continued support and passion for science!
About This Curation
These top 10 stories were automatically selected from 74 biotech business articles analyzed this week using our scoring algorithm. Each story is scored based on deal size, event significance, company prominence, innovation factor, and source credibility.
⭐ 10 Exciting Stories This Week
#1 ASCO26: In vivo oncology approaches continue to show promise
Pharmaceutical Technology
June 02, 2026
[Read Full Story] Eli Lilly’s $7 billion acquisition of Kelonia is delivering results, with the company’s in vivo oncology assets demonstrating clinical promise at ASCO 2026. Other companies are also advancing in vivo cancer therapies at the conference, suggesting the approach is gaining traction across the industry. The developments validate the investment rationale for large pharmaceutical acquisitions in this therapeutic area.
#2 Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact
FierceBiotech
[Read Full Story] Regeneron expanded its partnership with CytomX Therapeutics, paying $37 million upfront to develop conditionally active bispecific antibodies against two new targets, with options for additional programs. The deal brings total potential payments to approximately $4 billion, reflecting Regeneron’s bet on CytomX’s Probody platform technology that activates therapeutics selectively in diseased tissue. The expansion signals continued industry investment in next-generation antibody engineering approaches that aim to improve safety and efficacy over conventional biologics.
#3 Innovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC
FierceBiotech
[Read Full Story] Innovent Biologics reported positive phase 3 results for IBI343, an antibody-drug conjugate that Takeda acquired rights to in a $1.2 billion deal last year. The clinical win validates Takeda’s significant investment and strengthens the ADC’s path toward commercialization in what has become one of biotech’s most competitive therapeutic areas.
#4 Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases
FierceBiotech
[Read Full Story] Ascidian Therapeutics secured a research collaboration with Eli Lilly worth up to $1.9 billion to develop RNA exon editing therapies for genetic kidney diseases. The deal gives Lilly rights to discover and develop therapeutics using Ascidian’s RNA editing platform, marking a significant bet on an emerging gene therapy approach that modifies RNA rather than DNA. The partnership validates RNA exon editing as a potential treatment modality for genetic diseases affecting the kidney, an organ that has proven difficult to target with traditional gene therapies.
#5 ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
FierceBiotech
[Read Full Story] Bristol Myers Squibb’s $800 million bispecific antibody-drug conjugate targeting EGFR and HER3 delivered positive phase 3 results in Chinese patients with triple-negative breast cancer, positioning it as a potential competitor to established TROP2-targeted therapies. The first-in-class drug’s strong China trial data validates BMS’s acquisition strategy and signals emerging competition in the lucrative triple-negative breast cancer market currently dominated by TROP2 agents like Gilead’s Trodelvy. The results matter because they demonstrate an alternative mechanism of action that could capture market share in a indication where TROP2 drugs have become the standard of care.
#6 Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer
FierceBiotech
[Read Full Story] Alnylam signed a $2 billion partnership with Inceptive to use AI for designing RNA interference drugs, paying $30 million upfront to work with Jakob Uszkoreit, a co-creator of the transformer technology behind ChatGPT. The deal combines Alnylam’s RNA drug expertise with Inceptive’s AI platform to accelerate the development of siRNA therapeutics. This marks a major bet on AI-driven drug design from the RNAi therapy leader, potentially cutting years off development timelines for genetic medicines.
#7 Anti-aging biotech NewLimit raises $435M at $3B+ valuation
Endpoints News
June 02, 2026
[Read Full Story] NewLimit closed a $435 million Series B at a $3+ billion valuation, marking one of biotech’s largest private rounds in 2026. The Bay Area anti-aging startup plans to begin human trials for its first drug candidate in 2027. The financing demonstrates sustained investor appetite for longevity therapeutics despite broader biotech funding challenges.
#8 Travere pays Everest $112M upfront to grow rare kidney disease pipeline
Endpoints News
June 02, 2026
[Read Full Story] Travere Therapeutics paid Everest Medicines $112 million upfront to expand its rare kidney disease pipeline beyond its approved drug Filspari. The deal gives the San Diego biotech access to Everest’s development programs, strengthening its position in the rare kidney disease market. The acquisition addresses Travere’s need for additional pipeline assets to sustain growth after Filspari’s commercialization.
#9 Parabilis Medicines charts $413M IPO to back peptide pipeline
Endpoints News
June 04, 2026
[Read Full Story] Parabilis Medicines, led by former Johnson & Johnson R&D chief Mathai Mammen, filed for a $413 million Nasdaq IPO to advance its peptide drug pipeline. The offering would rank among the larger biotech debuts, signaling investor appetite for peptide therapeutics despite recent market volatility. The capital will fund clinical development of the company’s platform designed to create more stable, drug-like peptides.
#10 ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma
Pharmaceutical Technology
June 02, 2026
[Read Full Story] Kelonia presented early preclinical data on KLN-1010, a CAR-T therapy for multiple myeloma that Eli Lilly acquired in January 2025. The in vivo results suggest the treatment may offer better tolerability than AstraZeneca’s competing ESOT-01 therapy, though potentially at the cost of lower efficacy. The data marks an early validation for Lilly’s bet on Kelonia’s approach to multiple myeloma, a blood cancer market where CAR-T competition is intensifying.